Merck inks a licensing deal worth nearly $2B with China’s Jiangsu Hengrui
Merck (NYSE:MRK) has reached a licensing agreement worth nearly $2B with the Chinese drugmaker Jiangsu Hengrui ...
Merck buys rights to heart disease drug in latest China deal
Merck has signed a licensing deal with Jiangsu Hengrui Pharmaceuticals worth up to $2 billion for its experimental heart ...
China Daily4d
Jiangsu data centers drive grid expansion
The rapid establishment of big data centers in the industrial hub of Jiangsu province is driving massive electricity demand, prompting a 582 million yuan ($80 million) new grid investment from 2025 to ...
BioWorld4d
For nearly $2B, Jiangsu Hengrui licenses heart drug to Merck
In a deal that could reach nearly $2 billion, Jiangsu Hengrui Pharmaceuticals Co. Ltd. has licensed a small molecule for ...
Excitement Builds as China's National Football Team Faces Australia Tonight: Join the Jiangsu Sports Lottery Viewing Event!
As the clock ticks down to the highly anticipated showdown between the China national football team and Australia, excitement is palpable among fans. This eighth round of the 2026 FIFA World Cup Asia ...
CHINA-JIANGSU-SUZHOU-TEA-HARVEST (CN)
Farmers pick tea leaves at a tea garden of an agricultural demonstration park in Wuzhong District, ...
PharmExec5d
Merck Reaches Licensing Agreement with Jiangsu Hengrui for Novel Heart Disease Drug
Under terms of the deal, Merck will gain global rights to develop, manufacture, and commercialize HRS-5346 for cardiovascular ...